All results
1 results for sbrt lung non daily treatment
-
Oral IRAK-4 inhibitor CA-4948 in combination with Pembrolizumab following stereotactic radiosurgery
This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic…
- Ages
- 18 Years - 99 Years
- Sexes
- All